{
    "nct_id": "NCT05005442",
    "official_title": "A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] With MK-3475 [Pembrolizumab] Coformulation) in Participants With Relapsed or Refractory Hematological Malignancies",
    "inclusion_criteria": "Inclusion Criteria\n\n- Have confirmed relapsed/refractory classic Hodgkins Lyphoma (cHL), Primary mediastinal B-cell lymphoma (PMBCL), Follicular Lymphoma (FL), Diffuse large B-cell lymphoma (DLBCL) or Non-Hodgkins Lymphoma (NHL), or multiple myeloma (MM).\n\nFor PMBCL, DLBCL, FL, and MM:\n\n- Must be relapsed or refractory to CAR-T-cell therapy or unable to receive it.\n\nFor DLBCL and NHL:\n\n- Must have exhausted or be ineligible for or intolerant to all treatments, which in the opinion of the investigator are standard of care for their disease.\n\nFor NHL:\n\n- Participants with Mantle cell lymphoma (MCL) must have received prior Bruton's tyrosine kinase inhibitor therapy.\n\nAll participants:\n\n* Have measurable disease.\n* Have adequate organ function.\n* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation.\n* Must be able to provide newly obtained bone marrow biopsy or aspirate material for disease assessment.\n* Female participants are eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of non child-bearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle.\n\nExclusion Criteria\n\nFor DLBCL and NHL:\n\n- Has lymphoplasmacytic lymphomas, Waldenstrom's macroglobulinemia, chronic lymphocytic leukemia (not associated with small lymphocytic lymphoma), Burkitt (-like) lymphoma, mature T cell and NK cell neoplasms, immunodeficiency associated lymphoproliferative neoplasms, or histiocytic and dendritic cell neoplasms.\n\nFor MM:\n\n* Has oligo-secretory myeloma, plasma cell leukemia, smoldering multiple myeloma, or monoclonal gammopathy of undetermined significance.\n* Has a history of primary amyloidosis, hyperviscosity or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).\n* Has known prior or current central nervous system (CNS) involvement.\n\nFor Epstein Barr virus (EBV) positive DLBCL:\n\n- Associated with a solid organ transplant.\n\nFor all participants:\n\n* A WOCBP who has a positive urine pregnancy test within 72 hours before study intervention allocation.\n* Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.\n* Has a history of a second malignancy.\n* Any PMBCL participants that require the use of urgent cytoreductive therapy.\n* If the participant had major surgery, the participant must have recovered adequately from the procedure and/or any complications from the surgery before starting study intervention.\n* Has received prior radiotherapy within 2 weeks of start of study intervention.\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.\n* Has a known severe hypersensitivity to MK-7684A, vibostolimab or pembrolizumab and/or any of its excipients.\n* Has a known history of Human Immunodeficiency Virus (HIV) infection.\n* Has an active autoimmune disease that has required systemic treatment in past 2 years.\n* Has an active infection requiring systemic therapy.\n* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.\n* Has present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks before enrollment.\n* Has dual active HBV infection (HBsAg (+) and /or detectable HBV DNA) and Hepatitis C (HCV) infection (anti-HCV Ab (+) and detectable HCV RNA) at study entry..\n* Has had an allogenic hematopoietic stem cell/solid organ transplantation within the last 5 years.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}